Navigation Links
MPs in Biological Technology

Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision

Announces significant contract with Major Biopharmaceutical Company BELGIUM, Wis., March 6 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), is pleased to announce that its subsidiary, Modular Process Constructors LLC, is changing its name to MPS BioPharm to better reflect i...

BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome

NOVATO, Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome. BioMarin plans to initiate a Phase 1/2...

Kuvan Receives Priority Review Status From Health Canada

...ment for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Jefferies Healthcare Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Goldman Sachs Healthcare Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Deutsche Bank Health Care Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Baird Growth Stock Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin Announces First Quarter 2009 Financial Results

...g programs including PEG-PAL for PKU and GALNS for mps IVA. We are strategically developing earlier stag...ial are expected in mid-2010. GALNS for mps IVA: BioMarin initiated the Phase I/II trial in m... 1H10: Results from Phase I/II trial for GALNS for mps IVA Mid-2010: Results from PEG-PAL Phase I...

Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors

...ilize MPS' Equity by Design (TM) product. mps will evaluate all equipment designs for fit and pu...lated to design, constructability and cleanliness. mps will also provide a final report, identifying budg...id, "Equity by Design(TM) is a program whereby mps provides certain Technical Advisory Services in wh...

BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA

...me replacement therapies, one for the treatment of mps I and one for the treatment of mps VI. Naglazyme(R) (galsulfase) for mps VI is wholly developed and commercialized by BioMa...

BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results

...the advancement of several programs including PEG-PAL for PKU and GALNS for mps IVA. We also plan to continue making investments in growth opportunities a...se 2 PAH trial -- 1Q09/2Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 2Q09: Results from proteinuria in chronic kidney disease trial ...

Naglazyme Approved by Brazil's National Health Surveillance Agency

...zil which has the largest known number of affected mps VI patients in the world," said Stephen Aselage, S...) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...t exclusivity in the European Union. About mps VI ...

Mach One Corporation Enters Letter of Intent

...saction with Modular Process Constructors LLC (dba mps BioPharm) (the "Seller" or "BioPharm") to acquire ... About Modular Process Constructors LLC (dba mps BioPharm) mps BioPharm currently designs and builds skid based s...

Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics

... (galsulfase) and enzyme replacement therapies for mps IVA (Morquio Syndrome) and Pompe disease will be p...for symptomatic spinal cord compression (SCC) in a mps VI child: safety, efficacy, and pitfalls" 763/W ...ears of Galsulfase ERT in five adult patients with mps VI" 2353/W - "MPS Brazil-Network: 4 years improv...

BioMarin Announces Third Quarter 2008 Financial Results

...xpansion of Naglazyme, and the timely development of the PEG-PAL, GALNS for mps IVA and other promising pipeline programs." Net Product Revenue Net pro...ic kidney disease trial -- 1Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 1Q09/2Q09: Results from PEG-PAL Phase 1 trial -- 1Q09/2Q09: Initia...

Naglazyme Approved by Japanese Ministry of Health

...Ges in bringing the first drug treatment option to mps VI patients in Japan," said Stephen Aselage, Senio...C) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...ation in June 2007 from the MHLW in Japan. About mps VI ...

BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture

...rojects which could lead to important advances for mps I patients." About mps I mps I is a rare, progressive, heterogeneous, debilitat...

Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics

...e (galsulfase) Enzyme Replacement Therapy (ERT) in mps VI (Maroteaux-Lamy Syndrome) patients Presented b...sserstein) -- 1495 -- Clinical Characteristics of mps I patients in the mps I Registry (Bodamer) -- 2241 -- Urinary GAG ...

Genzyme Receives Approval to Market Elaprase(R) in Japan

... Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; Aldurazyme(R) (laronidase) for mps I; and Myozyme(R) (alglucosidase alfa) for Pompe disease. "Our deep experience in Japan in the area of lysosomal storage disorders will enable us to ...

Genzyme Begins Major Expansion of Boston Manufacturing Facility

... alfa) for Pompe disease. Genzyme also performs the filling and packaging for two products manufactured at other sites: Aldurazyme(R) (laronidase) for mps I disease and Thyrogen(R) (thyrotropin alfa for injection), used in the screening of patients who have had thyroid cancer. Genzyme last expanded the s...

Educate, innovate and execute: Wisconsins model for success

...m rather than how much is spent administratively. mps simply spends too much money on employee costs (i....nefits, pension) than is manageable. In fact, the mps Board boosted the tax levy for 2003-'04 by more th...$11 million, or a 5.8 percent increase. This year, mps is projecting a 15% increase as a stopgap to keep ...
Other Tags
(Date:7/13/2014)... of more effective treatments for cachexia, a profound wasting ... all cancer patients, raising their risk of death, according ... have been tried to reverse the condition, which may ... treatments, but none have had great success. , Scientists ... Nature , led by Bruce Spiegelman, PhD, demonstrated ...
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... bring attention to the cancer risks associated with power ... to tell their story to federal regulators, as they ... U.S. Food & Drug Administration (FDA) advisory panel ... reports. According to the Rochester Democrat and Chronicle, ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... Trujillo Alto, Puerto Rico (PRWEB) July 13, 2014 ... that NBA Hall of Famer, Chris Mullin, will be ... Meeting on Saturday, July 26th in Puerto Rico. ... opportunities. Chris Mullin will participate in two exhibition basketball ... Max International, the ultimate supplier of health- and ...
(Date:7/13/2014)... Dallas, Texas (PRWEB) July 13, 2014 ... of aGVHD in the 6MM, from 8,062 diagnosed incident ... 2023, at an Annual Growth Rate (AGR) of 4.35%, ... have the highest number of diagnosed incident cases of ... whereas Spain will have the lowest number of diagnosed ...
(Date:7/13/2014)... July 13, 2014 According to the Kidney ... a step by step guide on what to do to ... and quickly. Vkool writes in its review that readers can ... eat to revitalize their kidney health. Vkool also informs in ... people reverse their damaged kidney functions naturally. The book consists ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3
Other Contents